|
|
|
Volumn 26, Issue 10, 2012, Pages 896-
|
|
FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 (4 (((4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO) 3 FLUOROPHENOXY) N METHYLPYRIDINE 2 CARBOXAMIDE;
4-(4-(((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO)-3-FLUOROPHENOXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE;
ANTINEOPLASTIC AGENT;
CARBANILAMIDE DERIVATIVE;
PYRIDINE DERIVATIVE;
ARTICLE;
COLORECTAL TUMOR;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MORTALITY;
PATHOLOGY;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
COLORECTAL NEOPLASMS;
DRUG APPROVAL;
HUMANS;
PHENYLUREA COMPOUNDS;
PYRIDINES;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84871911684
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (28)
|
|
References (0)
|